Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00— vs Q2 2024 Net Income-$7.36M-$7.36MN/M vs Q2 2024 EPS Diluted-$0.33-$0.33N/M vs Q2 2024 Operating Income-$8,610,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
ended Dec 31, 2024 · filed Feb 14, 2025 · 45 d after period end